2024
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
Aguirre L, Jain A, Ball S, Ali N, Volpe V, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 459-467. PMID: 38548563, DOI: 10.1016/j.clml.2024.03.001.Peer-Reviewed Original ResearchConceptsRate of leukemic transformationResponse to ruxolitinibLeukemic transformationPercentage of marrow blastsAssessment of treatment responseH. Lee Moffitt Cancer CenterPhenotypic driver mutationsNegative myeloproliferative neoplasmsHigh-risk diseaseAggressive clinical behaviorDiagnosis of myelofibrosisProportion of patientsOverall survival timeMoffitt Cancer CenterShort durationMarrow blastsTrisomy 8Epigenetic modificationsTN patientsAggressive courseRisk diseaseClinical presentationMyeloproliferative neoplasmsInferior outcomesClinical behavior
2023
Improved Overall Survival Among Luspatercept Responders and Predictors of Response
Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, Andreossi G, Rigodanza L, Sanna A, Raddi M, Walker A, Kuykendall A, Lancet J, Padron E, Sallman D, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Campagna A, Della Porta M, Santini V, Komrokji R. Improved Overall Survival Among Luspatercept Responders and Predictors of Response. Blood 2023, 142: 1871. DOI: 10.1182/blood-2023-186279.Peer-Reviewed Original ResearchMoffitt Cancer CenterIPSS-MMedian OSRBC-TDRBC-TIErythroid stimulating agentsHematologic responsePredictors of responseOverall survivalNon-respondersHgb increasesTransfusion burdenHypomethylating agentsRinged sideroblastsLR-MDSAdverse eventsFirst-in-class erythroid maturation agentAssociated with improved OSMedian duration of responseLow-risk myelodysplastic syndromesRed blood cell transfusionErythroid maturation agentLow TB groupMedian OS benefitRBC transfusion burdenRefining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.
Aguirre L, Jain A, Ball S, Al Ali N, Sallman D, Kuykendall A, Chan O, Xie Z, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models. Journal Of Clinical Oncology 2023, 41: 7020-7020. DOI: 10.1200/jco.2023.41.16_suppl.7020.Peer-Reviewed Original ResearchCPSS-MolIPSS-MPrognostic accuracyCumulative incidenceHarrell's C concordance indexPredictive valueMedian Follow-UpRefining risk stratificationMoffitt Cancer CenterTime-to-event analysisIPSS-RAML evolutionRisk stratificationAML riskKaplan-MeierC-indexCMMLFollow-upCox regressionRisk groupsCancer CenterMolecular dataTreatment decisionsHigh riskSurvival endpointsAssessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes
Aguirre L, Al Ali N, Sallman D, Ball S, Jain A, Chan O, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia 2023, 37: 1530-1539. PMID: 37147425, DOI: 10.1038/s41375-023-01910-3.Peer-Reviewed Original ResearchConceptsLeukemia-free survivalMolecular International Prognostic Scoring SystemInternational Prognostic Scoring SystemPrognostic scoring systemMyelodysplastic syndromeIPSS-MIPSS-ROverall survivalLeukemic transformationPrognostic accuracyCohort of MDS patientsMedian leukemia-free survivalScoring systemHypoplastic myelodysplastic syndromeMyelodysplastic syndrome patientsAccurate prognostic assessmentRisk stratification modelTherapeutic decision-makingVery-high-riskMoffitt Cancer CenterMedian OSMDS patientsT-MDSTherapy-relatedPrognostic assessmentSex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes
Tinsley-Vance S, Ali N, Ball S, Aguirre L, Jain A, Hussaini M, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2023, 23: 355-359. PMID: 36813626, PMCID: PMC10121764, DOI: 10.1016/j.clml.2023.01.007.Peer-Reviewed Original ResearchConceptsMedian overall survivalLower-risk MDSHigher-risk MDSHigher platelet countMoffitt Cancer CenterOverall survivalMyelodysplastic syndromeRUNX1 mutationsPlatelet countFemale patientsImpact of biological sexLow hemoglobinImpact of sexClinical phenotypeCancer CenterMolecular profilingPatientsSex disparitiesWomenMDS databaseMenPhenotypeOutcomesSexGenotypes
2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients
Ball S, Aguirre L, Jain A, Ali N, Tinsley S, Chan O, Kuykendall A, Sweet K, Lancet J, Sallman D, Hussaini M, Padron E, Komrokji R. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leukemia Research 2022, 124: 106999. PMID: 36542963, DOI: 10.1016/j.leukres.2022.106999.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeMedian OSEZH2 mutationsAssociated with inferior median OSAssociated with significantly worse OSMedian OS of patientsSingle-center retrospective studyInferior median OSIPSS-R categoryOS of patientsChromosome 7 abnormalitiesMoffitt Cancer CenterCo-occurring mutationsDeterminants of outcomeEZH2-mutationHypomethylating agentsRUNX1 mutationsMyeloid neoplasmsClinical characteristicsRetrospective studyClinical trialsCancer CenterPatientsImprove outcomesASXL1AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen
Jain A, Wang C, Ball S, Aguirre L, Schwabkey Z, Tobon K, Kuykendall A, Chan O, Padron E, Lancet J, Komrokji R, Sweet K, Sallman D. AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s258-s259. DOI: 10.1016/s2152-2650(22)01310-6.Peer-Reviewed Original ResearchGemtuzumab ozogamicinMRD negativityPost-inductionDay 1Transplantation-related mortalityTreatment related mortalityPost-consolidationMoffitt Cancer CenterAntibody-drug conjugatesMedian followDiagnosed AMLMedian ageRetrospective analysisCancer CenterRelated mortalityPatientsMonoclonal antibodiesCohortRFSOzogamicinRegimenOSMortalityAlloSCTGemtuzumabMDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
Aguirre L, Al Ali N, Sallman D, Jain A, Ball S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s320. DOI: 10.1016/s2152-2650(22)01426-4.Peer-Reviewed Original ResearchMedian overall survivalChronic myelomonocytic leukemiaDNMT3A mutationsMyelomonocytic leukemiaRelapse rateMedian duration of follow-upAllogeneic stem cell transplantationDuration of follow-upStem cell transplantationRisk of relapseStem cell sourceMoffitt Cancer CenterTransplant-related variablesConditioning regimenCMML patientsBlast percentageIntensive chemotherapyCurative optionOverall survivalAllogeneic transplantationCMML-2Median durationCell transplantationMedian ageInduce CRHyperferritinemia as predictive biomarker of poor clinical outcomes in CMML.
Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Hyperferritinemia as predictive biomarker of poor clinical outcomes in CMML. Journal Of Clinical Oncology 2022, 40: 7055-7055. DOI: 10.1200/jco.2022.40.16_suppl.7055.Peer-Reviewed Original ResearchAML transformationTransfusion dependenceFerritin levelsBiomarker of poor clinical outcomeMultivariate analysisRisk of myeloid malignanciesAssociated with more aggressive diseaseBiomarkers of disease activityHigh-risk diseasePoor clinical outcomesRisk of poor outcomesHistory of infectionMoffitt Cancer CenterAssociated with inflammationIPSS-RPeripheral blastsAnalysis of gene signaturesCMML-2Myeloid malignanciesEstimate OSAggressive diseaseRisk diseaseMedian ageDismal outcomeHigher ferritin
2021
Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS)
Brunner A, Gavralidis A, Al Ali N, Komrokji R, Zeidan A, Sallman D. Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS). Blood 2021, 138: 1522. DOI: 10.1182/blood-2021-151815.Peer-Reviewed Original ResearchClinical Trials CommitteeStable diseaseComplete remissionHMA therapyBone marrow blastsHematologic improvementProgressive diseaseMyelodysplastic syndromePartial remissionTrials CommitteeResponse criteriaMarrow blastsOverall survivalSpeakers bureauHigh-risk myelodysplastic syndromeAdvisory CommitteeIncomplete hematologic recoveryIWG 2006 criteriaMethod of KaplanRisk myelodysplastic syndromesOngoing prospective studyMoffitt Cancer CenterBest overall responsePrediction of OSMassachusetts General HospitalCharacterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment
Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment. Blood 2021, 138: 1523. DOI: 10.1182/blood-2021-149283.Peer-Reviewed Original ResearchMedian overall survivalEntity's Board of DirectorsMoffitt Cancer CenterM:E ratioClonal evolutionIndolent diseaseIndolent courseMyeloproliferative neoplasmsLonger time to treatmentDiagnosis of CMMLAssociated with poor outcomesLow-risk diseaseMolecular featuresIndolent disease courseInitiation of therapyHigher platelet countClinical declineMultiple prognostic modelsAssociated with better outcomesInitiation of treatmentAssociated with longer times to treatmentWorsening clinical symptomsTime to treatmentAssociated with early initiationMonths prior to treatmentGender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes
Tinsley-Vance S, Al Ali N, Ball S, Aguirre L, Jain A, Kaldas D, Chan O, Padron E, Sweet K, Lancet J, Kuykendall A, Sallman D, Komrokji R. Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood 2021, 138: 1984. DOI: 10.1182/blood-2021-149894.Peer-Reviewed Original ResearchMedian overall survivalEntity's Board of DirectorsAllogeneic hematopoietic stem cell transplantationMyelodysplastic syndromeR-IPSSAdvisory CommitteeOverall survivalResearch fundingLower-risk myelodysplastic syndromesLow-risk myelodysplastic syndromesTherapy-related myelodysplastic syndromeHigher-risk myelodysplastic syndromesResponse to immunosuppressive therapyHematopoietic stem cell transplantationMDS databaseRisk myelodysplastic syndromesStem cell transplantationErythroid stimulating agentsSEER registriesKaplan-Meier methodChi-square testHigher platelet countGender differencesCompare categorical variablesMoffitt Cancer CenterTriple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood 2021, 138: 1494. DOI: 10.1182/blood-2021-151978.Peer-Reviewed Original ResearchLeukemia-free survivalEntity's Board of DirectorsTN diseaseMedian OSOverall survivalTN patientsConstitutional symptomsMyeloproliferative neoplasmsNon-TN patientsBCR-ABL1 negative myeloproliferative neoplasmsMedian leukemia-free survivalPresence of constitutional symptomsResponse to ruxolitinibTransformation to AMLHigher-risk diseaseNegative myeloproliferative neoplasmsAggressive clinical courseDiagnosis of MFKaplan-Meier methodShorter survival rateMoffitt Cancer CenterAdvisory CommitteeBlood cell productionCTI BioPharmaTN cohortClinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics
Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics. Blood 2021, 138: 2571. DOI: 10.1182/blood-2021-152026.Peer-Reviewed Original ResearchMonths of diagnosisPrimary myelofibrosisActive surveillanceMedian OSMyeloproliferative neoplasmsBCR-ABL1 negative myeloproliferative neoplasmsNegative myeloproliferative neoplasmsTriple-negative diseasePercentage of circulating blastsPrognostic scoring systemDiagnosis of MFRates of anemiaLower-risk patientsMoffitt Cancer CenterDisease-related symptomsKaryotypic riskSymptomatic splenomegalyMarrow myeloblastsTransfusion dependenceConstitutional symptomsJAK2 mutationBCR-ABL1No significant differenceAggressive subtypeBaseline characteristicsAML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia
Ball S, Jain A, Al Ali N, Hayden A, Swoboda D, Aguirre L, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Pollyea D, Komrokji R. AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s293. DOI: 10.1016/s2152-2650(21)01700-6.Peer-Reviewed Original ResearchAcute myeloid leukemiaFavorable-risk acute myeloid leukemiaIntensive chemotherapyOverall survivalCore binding factorIC groupMedian OSComplete remissionInduction regimensCBF-AMLMyeloid leukemiaIndependent predictorsFavorable-risk AML patientsAllogeneic stem cell transplantationRate of complete remissionSecondary acute myeloid leukemiaIndependent predictor of survivalMedian blast countIncomplete count recoveryStem cell transplantationPredictors of survivalInduction-related mortalityMoffitt Cancer CenterComposite CRFavorable-riskInvestigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR).
Noor A, Aguirre L, Blue K, Avriett T, Carballido E, Kim R, Kim D. Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR). Journal Of Clinical Oncology 2021, 39: 415-415. DOI: 10.1200/jco.2021.39.3_suppl.415.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPancreatic adenocarcinomaProgressive diseaseStable diseaseMetastatic diseaseEfficacy of immune checkpoint inhibitorsFollow-upTreated with immune checkpoint inhibitorsMedian duration of responseMedian progression-free survivalMedian overall survivalProgression-free survivalEfficacy of immunotherapyDuration of responseMedian Follow-UpTreatment of pancreatic adenocarcinomaMoffitt Cancer CenterAssociated rashCheckpoint inhibitorsResectable diseaseSystemic steroidsOverall survivalMedian durationMedian FUMismatch repair deficiency
2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions
Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins MB, Tawbi H, Boire A, Forsyth P. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell & Melanoma Research 2020, 33: 527-541. PMID: 31916400, PMCID: PMC10126834, DOI: 10.1111/pcmr.12861.Peer-Reviewed Original ResearchConceptsLeptomeningeal diseaseMelanoma patientsCentral nervous system metastasesMelanoma Research FoundationParenchymal brain metastasesNervous system metastasesMoffitt Cancer CenterMultiple academic centersBrain metastasesCancer CenterTherapeutic managementAcademic centersClinical researchDeadly diseaseConsensus summaryDiseasePatientsMetastasisSecond summit
2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate‐Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell & Melanoma Research 2019, 32: 458-469. PMID: 30712316, PMCID: PMC7771318, DOI: 10.1111/pcmr.12771.Peer-Reviewed Original Research
2013
The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
Zeidan A, Al Ali N, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette P, Lancet J, List A, Komrokji R. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza). Blood 2013, 122: 2771. DOI: 10.1182/blood.v122.21.2771.2771.Peer-Reviewed Original ResearchMD Anderson Prognostic Scoring SystemMedian overall survivalHigh-risk groupMoffitt Cancer CenterAZA therapyHR-MDSOverall survivalPrognostic scoring systemMyelodysplastic syndromeIntermediate riskRisk groupsLower riskScoring systemPrognostic groupsInt-2Therapy-related myelodysplastic syndromeHigh-risk myelodysplastic syndromeCycles of therapyHR-MDS patientsKaplan-Meier curvesLog-rank testOff-label useAZA initiationRevised IPSSR-IPSS
2012
The Surgical Treatment of Breast Cancer in the Elderly: A Single Institution Comparative Review of 5235 Patients with 1028 Patients ≥70 years
Kaur P, Santillan A, McGuire K, Turaga K, Shamehdi C, Meade T, Ramos D, Mathias M, Parbhoo J, Davis M, Khakpour N, King J, Balducci L, Cox C. The Surgical Treatment of Breast Cancer in the Elderly: A Single Institution Comparative Review of 5235 Patients with 1028 Patients ≥70 years. The Breast Journal 2012, 18: 428-435. PMID: 22957995, DOI: 10.1111/j.1524-4741.2012.01272.x.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryDuctal carcinoma in situSurgical management of breast cancerManagement of breast cancerYears of ageBreast cancerInvasive carcinomaSurgical managementElderly womenSurgical treatment of breast cancerBreast-conserving surgery rateTreatment of breast cancerExtent of surgeryCarcinoma in situStandard surgical procedureMoffitt Cancer CenterBreast cancer treatmentDemographics of patientsConservative surgeryMastectomy ratesOperative mortalityRetrospective reviewSurgical mortalitySurgical treatmentStandard treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply